Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.63 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17940319 | 0.88 | SCN9A (0.61) | SCN9APTPN1SCN5ATRPV1MAPT | |
| SCHEMBL17940326 | 0.78 | SCN9A (0.62) | SCN9APTPN1SCN5AHDAC8HDAC6 | |
| SCHEMBL17940269 | 0.78 | SCN9A (1.00) | SCN9A | |
| SCHEMBL679785 | 0.77 | MCL1 (0.62) | SCN9ATRPV1HDAC8BCL2L1MCL1 | |
| SCHEMBL16319187 | 0.75 | MAPK14 (0.56) | SCN9APTPN1SCN5ANPC1RAB9A | |
| SCHEMBL31331542 | 0.73 | SCN9A (0.64) | SCN9APTPN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17940179 | 0.72 | SCN9A (0.62) | SCN9APTPN1SCN5ATRPV1 | |
| SCHEMBL369173 | 0.72 | MAPK14 (0.53) | SCN9APTPN1SCN5ANPC1RAB9A | |
| SCHEMBL680539 | 0.72 | HDAC8 (0.47) | SCN9APTPN1SCN5ANPC1RAB9A | |
| SCHEMBL17940422 | 0.72 | SCN9A (0.50) | SCN9ANPC1RAB9ASMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | SCN9A 9/4885PTPN5 1055/4885PTPN1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.